FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997332482> ?p ?o ?g. }

• W2997332482 endingPage "3025" @default.
• W2997332482 startingPage "3025" @default.
• W2997332482 abstract "3025 Introduction: Sodium iodide symporter (NIS) is expressed in human hepatocellular carcinoma (HCA) and certain breast carcinomas (BCA), however, the effective treatment of these cancers using radioactive iodine (RAI) is contingent upon constitutive and stronger expression of NIS. It has been shown that doxorubicin induces selective expression of NIS in HCA by activation of p63 and p73 binding to NIS promoter, leading to an increased expression of NIS mRNA and protein in HCA cells but not in primary human hepatocytes. We tested the hypothesis that doxorubicin can be used effectively to upregulate NIS-expression in HCA, BCA and Colon Carcinoma (CCA). This proposal was tested in the following three specific aims: Aim 1) To demonstrate that doxorubicin can be used viably on cultured HCA, BCA, and CCA cells. Aim 2) To demonstrate that doxorubicin can selectively induce NIS expression in BCA cells. Aim 3) To demonstrate that doxorubicin can selectively induce NIS expression in CCA cells. We were able to successfully culture HCA, BCA, and CCA cells in vitro and treat these cells with varying concentrations of doxorubicin without loss of cell viability. We were then able to extract the total proteins from BCA and CCA cells respectively and perform NIS protein expression studies using western blot. Our results demonstrate that HCA, BCA, and CCA cells can be treated with doxorubicin without loss of cell viability and doxorubicin upregulates the expression of NIS protein strongly in BCA cells (Fig. 1) and at low levels in CCA cells (Fig. 2). The findings of these studies will enable us to investigate further the use of radioiodine to treat these deadly cancers which can significantly contribute to our efforts in improving patient prognosis.Figure 1.Western blot results demonstrates that doxorubicin upregulates sodium iodide symporter (NIS) in MDA-MB231 breast cancer cells. MDA-MB231 cells were not treated (0) or treated with 0.2µM, 2µM, or 20µM doxorubicin hydrochloride for 48 hours. After equal loading, total cell proteins were separated on SDS-polyacrylamide gel and subsequently transferred to nitrocellulose membrane. The NIS protein levels were determined by western blot using goat anti-NIS primary antibody and rabbit antigoat secondary antibody.Figure 2. Visualization of sodium iodide symporter at low levels in the 2 uM doxorubicin-treated colon cancer sample. NaI symporter expression in SW620 cells was assessed by treating SW620 cells with doxorubicin at 2μM for 48 hrs, followed by washing with PBS. Cells were lysed in lysis buffer and 1μg of protein was resolved by Polyacrylamide Gel Electrophoresis. Proteins were transferred to a Polyvinylidene difluoride membrane, probed with a rabbit anti-NIS polyclonal IgG antibody and mmunodetected using a secondary rabbit antibody and detected chromogenically using TMB substrate." @default.
• W2997332482 created "2020-01-10" @default.
• W2997332482 creator A5009469696 @default.
• W2997332482 creator A5024446851 @default.
• W2997332482 creator A5036278569 @default.
• W2997332482 creator A5041477761 @default.
• W2997332482 creator A5053763290 @default.
• W2997332482 creator A5054818445 @default.
• W2997332482 creator A5072263750 @default.
• W2997332482 date "2019-05-01" @default.
• W2997332482 modified "2023-09-27" @default.
• W2997332482 title "Use of Doxorubicin for Radioiodine Targeted Therapy of Treatment Resistant Metastatic Breast Cancer, Hepatocellular Cancer, and Colon Cancer" @default.
• W2997332482 hasPublicationYear "2019" @default.
• W2997332482 type Work @default.
• W2997332482 sameAs 2997332482 @default.
• W2997332482 citedByCount "0" @default.
• W2997332482 crossrefType "journal-article" @default.
• W2997332482 hasAuthorship W2997332482A5009469696 @default.
• W2997332482 hasAuthorship W2997332482A5024446851 @default.
• W2997332482 hasAuthorship W2997332482A5036278569 @default.
• W2997332482 hasAuthorship W2997332482A5041477761 @default.
• W2997332482 hasAuthorship W2997332482A5053763290 @default.
• W2997332482 hasAuthorship W2997332482A5054818445 @default.
• W2997332482 hasAuthorship W2997332482A5072263750 @default.
• W2997332482 hasConcept C104317684 @default.
• W2997332482 hasConcept C121608353 @default.
• W2997332482 hasConcept C126322002 @default.
• W2997332482 hasConcept C127561419 @default.
• W2997332482 hasConcept C1491633281 @default.
• W2997332482 hasConcept C185592680 @default.
• W2997332482 hasConcept C2776415932 @default.
• W2997332482 hasConcept C2776694085 @default.
• W2997332482 hasConcept C2778019345 @default.
• W2997332482 hasConcept C2781303535 @default.
• W2997332482 hasConcept C502942594 @default.
• W2997332482 hasConcept C53227056 @default.
• W2997332482 hasConcept C54355233 @default.
• W2997332482 hasConcept C55493867 @default.
• W2997332482 hasConcept C71924100 @default.
• W2997332482 hasConcept C81885089 @default.
• W2997332482 hasConcept C86803240 @default.
• W2997332482 hasConcept C96232424 @default.
• W2997332482 hasConceptScore W2997332482C104317684 @default.
• W2997332482 hasConceptScore W2997332482C121608353 @default.
• W2997332482 hasConceptScore W2997332482C126322002 @default.
• W2997332482 hasConceptScore W2997332482C127561419 @default.
• W2997332482 hasConceptScore W2997332482C1491633281 @default.
• W2997332482 hasConceptScore W2997332482C185592680 @default.
• W2997332482 hasConceptScore W2997332482C2776415932 @default.
• W2997332482 hasConceptScore W2997332482C2776694085 @default.
• W2997332482 hasConceptScore W2997332482C2778019345 @default.
• W2997332482 hasConceptScore W2997332482C2781303535 @default.
• W2997332482 hasConceptScore W2997332482C502942594 @default.
• W2997332482 hasConceptScore W2997332482C53227056 @default.
• W2997332482 hasConceptScore W2997332482C54355233 @default.
• W2997332482 hasConceptScore W2997332482C55493867 @default.
• W2997332482 hasConceptScore W2997332482C71924100 @default.
• W2997332482 hasConceptScore W2997332482C81885089 @default.
• W2997332482 hasConceptScore W2997332482C86803240 @default.
• W2997332482 hasConceptScore W2997332482C96232424 @default.
• W2997332482 hasLocation W29973324821 @default.
• W2997332482 hasOpenAccess W2997332482 @default.
• W2997332482 hasPrimaryLocation W29973324821 @default.
• W2997332482 hasRelatedWork W117644370 @default.
• W2997332482 hasRelatedWork W1871290325 @default.
• W2997332482 hasRelatedWork W1880937167 @default.
• W2997332482 hasRelatedWork W1964746080 @default.
• W2997332482 hasRelatedWork W1966948969 @default.
• W2997332482 hasRelatedWork W1983156626 @default.
• W2997332482 hasRelatedWork W198350416 @default.
• W2997332482 hasRelatedWork W2057572740 @default.
• W2997332482 hasRelatedWork W2063108966 @default.
• W2997332482 hasRelatedWork W2116249338 @default.
• W2997332482 hasRelatedWork W2360291526 @default.
• W2997332482 hasRelatedWork W2369504641 @default.
• W2997332482 hasRelatedWork W2384056100 @default.
• W2997332482 hasRelatedWork W2391177269 @default.
• W2997332482 hasRelatedWork W2394003978 @default.
• W2997332482 hasRelatedWork W2407221538 @default.
• W2997332482 hasRelatedWork W2419788856 @default.
• W2997332482 hasRelatedWork W2588248925 @default.
• W2997332482 hasRelatedWork W2964978587 @default.
• W2997332482 hasRelatedWork W3210187563 @default.
• W2997332482 hasVolume "60" @default.
• W2997332482 isParatext "false" @default.
• W2997332482 isRetracted "false" @default.
• W2997332482 magId "2997332482" @default.
• W2997332482 workType "article" @default.